Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan

Value in Health Regional Issues(2024)10.1016/j.vhri.2023.11.003Source: DataRank Database

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan is a research paper published in Value in Health Regional Issues (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.56)OA: hybridTopics (30)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Kensuke Moriwaki ORCID,Kosuke Morimoto,Xiuting Mo ORCID,Takashi Yoshioka ORCID,Rei Goto ORCID

Live enrichment

PubMed:38194896 OpenAlex:https://openalex.org/W4390684625

National Institutes of Health

FWCI

0.56

Citation Percentile

0.6%

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttp://www.valuehealthregionalissues.com/article/S2212109923001243/pdf

publisherhttp://www.valuehealthregionalissues.com/article/S2212109923001243/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2212109923001243?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2212109923001243?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.vhri.2023.11.003

Fields of Study

Renal cell carcinoma treatmentHealth Systems, Economic Evaluations, Quality of LifeCancer Immunotherapy and BiomarkersHumansCarcinoma, Renal CellNivolumabIpilimumabJapanCost-Effectiveness AnalysisAntineoplastic Combined Chemotherapy ProtocolsKidney Neoplasms

MeSH Terms

IpilimumabNivolumabCost-Effectiveness AnalysisAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellHumansJapanKidney Neoplasms

Keywords

NivolumabIpilimumabRenal cell carcinomaMedicineOncologyInternal medicineImmunotherapyCancerCost-effectiveness AnalysisAdvanced Renal Cell CarcinomaIpilimumab Japan

Sustainable Development Goals

SDG 0: No poverty